{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:19:02Z","timestamp":1786979942508,"version":"build-2736575974"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1007\/s00280-023-04518-7","type":"journal-article","created":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T07:03:42Z","timestamp":1679468622000},"page":"257-266","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Assay performance and stability of uracil and dihydrouracil in clinical practice"],"prefix":"10.1007","volume":"91","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6798-7247","authenticated-orcid":false,"given":"Jonathan E.","family":"Knikman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilde","family":"Rosing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henk-Jan","family":"Guchelaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annemieke","family":"Cats","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos H.","family":"Beijnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,11]]},"reference":[{"key":"4518_CR1","doi-asserted-by":"publisher","first-page":"2282","DOI":"10.1200\/jco.2001.19.8.2282","volume":"19","author":"PM Hoff","year":"2017","unstructured":"Hoff PM, Ansari R, Batist G et al (2017) Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 19:2282\u20132292. https:\/\/doi.org\/10.1200\/jco.2001.19.8.2282","journal-title":"J Clin Oncol"},{"key":"4518_CR2","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/nrc1074","volume":"3","author":"DB Longley","year":"2003","unstructured":"Longley DB, Harkin DP, Johnston PG (2003) 5-Fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 3:330\u2013338. https:\/\/doi.org\/10.1038\/nrc1074","journal-title":"Nat Rev Cancer"},{"key":"4518_CR3","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.ctrv.2016.08.002","volume":"50","author":"D Meulendijks","year":"2016","unstructured":"Meulendijks D, Cats A, Beijnen JH, Schellens JHM (2016) Improving safety of fluoropyrimidine chemotherapy by individualizing treatment based on dihydropyrimidine dehydrogenase activity\u2013ready for clinical practice? Cancer Treat Rev 50:23\u201334. https:\/\/doi.org\/10.1016\/j.ctrv.2016.08.002","journal-title":"Cancer Treat Rev"},{"key":"4518_CR4","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1002\/onco.13967","volume":"26","author":"BB Sharma","year":"2021","unstructured":"Sharma BB, Rai K, Blunt H et al (2021) Pathogenic DPYD variants and treatment-related mortality in patients receiving fluoropyrimidine chemotherapy: a systematic review and meta-analysis. Oncologist 26:1008\u20131016. https:\/\/doi.org\/10.1002\/onco.13967","journal-title":"Oncologist"},{"key":"4518_CR5","doi-asserted-by":"publisher","first-page":"4097","DOI":"10.1200\/JCO.2001.19.21.4097","volume":"19","author":"BE van Cutsem","year":"2010","unstructured":"van Cutsem BE, Twelves C, Cassidy J et al (2010) Fluorouracil plus leucovorin in patients with metastatic colorectal cancer\u202f: results of a large phase III study. J Clin Oncol 19:4097\u20134106","journal-title":"J Clin Oncol"},{"key":"4518_CR6","doi-asserted-by":"publisher","first-page":"215","DOI":"10.2165\/00003088-198916040-00002","volume":"16","author":"RB Diasio","year":"1989","unstructured":"Diasio RB, Harris BE (1989) Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet 16:215\u2013237. https:\/\/doi.org\/10.2165\/00003088-198916040-00002","journal-title":"Clin Pharmacokinet"},{"key":"4518_CR7","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.2217\/PGS.15.70","volume":"16","author":"LM Henricks","year":"2015","unstructured":"Henricks LM, Lunenburg CATC, Meulendijks D et al (2015) Translating DPYD genotype into DPD phenotype: Using the DPYD gene activity score. Pharmacogenomics 16:1277\u20131286. https:\/\/doi.org\/10.2217\/PGS.15.70","journal-title":"Pharmacogenomics"},{"key":"4518_CR8","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1016\/S1470-2045(15)00286-7","volume":"16","author":"D Meulendijks","year":"2015","unstructured":"Meulendijks D, Henricks LM, Sonke GS et al (2015) Clinical relevance of DPYD variants c.1679T>G, c.1236G>A\/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data. Lancet Oncol 16:1639\u20131650. https:\/\/doi.org\/10.1016\/S1470-2045(15)00286-7","journal-title":"Lancet Oncol"},{"key":"4518_CR9","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1200\/JCO.2015.63.1325","volume":"34","author":"MJ Deenen","year":"2016","unstructured":"Deenen MJ, Meulendijks D, Cats A et al (2016) Upfront genotyping of DPYD\u22172A to individualize fluoropyrimidine therapy: a safety and cost analysis. J Clin Oncol 34:227\u2013234. https:\/\/doi.org\/10.1200\/JCO.2015.63.1325","journal-title":"J Clin Oncol"},{"key":"4518_CR10","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1016\/S1470-2045(18)30686-7","volume":"2045","author":"LM Henricks","year":"2018","unstructured":"Henricks LM, Lunenburg CATC, de Man FM et al (2018) DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis. Lancet Oncol 2045:1459\u20131467. https:\/\/doi.org\/10.1016\/S1470-2045(18)30686-7","journal-title":"Lancet Oncol"},{"key":"4518_CR11","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1038\/bjc.2017.94","volume":"116","author":"D Meulendijks","year":"2017","unstructured":"Meulendijks D, Henricks LM, Jacobs BAW et al (2017) Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity. Br J Cancer 116:1415\u20131424. https:\/\/doi.org\/10.1038\/bjc.2017.94","journal-title":"Br J Cancer"},{"key":"4518_CR12","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.2217\/pgs.14.126","volume":"15","author":"J Sistonen","year":"2014","unstructured":"Sistonen J, B\u00fcchel B, Froehlich TK et al (2014) Predicting 5-fluorouracil toxicity: DPD genotype and 5,6-dihydrouracil:uracil ratio. Pharmacogenomics 15:1653\u20131666. https:\/\/doi.org\/10.2217\/pgs.14.126","journal-title":"Pharmacogenomics"},{"key":"4518_CR13","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1002\/cpt.2069","volume":"109","author":"JE Knikman","year":"2021","unstructured":"Knikman JE, Gelderblom H, Beijnen JH et al (2021) Individualized dosing of fluoropyrimidine-based chemotherapy to prevent severe fluoropyrimidine-related toxicity: what are the options? Clin Pharmacol Ther 109:591\u2013604. https:\/\/doi.org\/10.1002\/cpt.2069","journal-title":"Clin Pharmacol Ther"},{"key":"4518_CR14","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/sj.bjp.0705651","volume":"141","author":"H Jiang","year":"2004","unstructured":"Jiang H, Lu J, Ji J (2004) Circadian rhythm of dihydrouracil\/uracil ratios in biological fluids: a potential biomarker for dihydropyrimidine dehydrogenase levels. Br J Pharmacol 141:616\u2013623. https:\/\/doi.org\/10.1038\/sj.bjp.0705651","journal-title":"Br J Pharmacol"},{"key":"4518_CR15","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.canlet.2006.09.006","volume":"249","author":"M Boisdron-Celle","year":"2007","unstructured":"Boisdron-Celle M, Remaud G, Traore S et al (2007) 5-Fluorouracil-related severe toxicity: a comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency. Cancer Lett 249:271\u2013282. https:\/\/doi.org\/10.1016\/j.canlet.2006.09.006","journal-title":"Cancer Lett"},{"key":"4518_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0175998","volume":"12","author":"MC Etienne-Grimaldi","year":"2017","unstructured":"Etienne-Grimaldi MC, Boyer JC, Beroud C et al (2017) New advances in DPYD genotype and risk of severe toxicity under capecitabine. PLoS ONE 12:1\u201319. https:\/\/doi.org\/10.1371\/journal.pone.0175998","journal-title":"PLoS ONE"},{"key":"4518_CR17","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1002\/cpt.2608","volume":"112","author":"M With","year":"2022","unstructured":"With M, Knikman J, Man FM et al (2022) Dihydropyrimidine dehydrogenase phenotyping using pretreatment uracil: a note of caution based on a large prospective clinical study. Clin Pharmacol Ther 112:62\u201368. https:\/\/doi.org\/10.1002\/cpt.2608","journal-title":"Clin Pharmacol Ther"},{"key":"4518_CR18","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13719","author":"LM Henricks","year":"2018","unstructured":"Henricks LM, Jacobs BAW, Meulendijks D et al (2018) Food-effect study on uracil and dihydrouracil plasma levels as marker for dihydropyrimidine dehydrogenase activity in human volunteers. Br J Clin Pharmacol. https:\/\/doi.org\/10.1111\/bcp.13719","journal-title":"Br J Clin Pharmacol"},{"key":"4518_CR19","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1016\/j.annonc.2021.02.020","volume":"32","author":"F Thomas","year":"2021","unstructured":"Thomas F, Maillard M, Launay M et al (2021) Artificial increase of uracilemia during fluoropyrimidine treatment can lead to DPD deficiency misinterpretation. Ann Oncol 32:810\u2013811. https:\/\/doi.org\/10.1016\/j.annonc.2021.02.020","journal-title":"Ann Oncol"},{"key":"4518_CR20","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15482","author":"L Carriat","year":"2022","unstructured":"Carriat L, Quaranta S, Solas C et al (2022) Renal impairment and DPD testing: Watch out for false-positive results! Br J Clin Pharmacol. https:\/\/doi.org\/10.1111\/bcp.15482","journal-title":"Br J Clin Pharmacol"},{"key":"4518_CR21","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1007\/s00280-021-04354-7","volume":"88","author":"C Gaible","year":"2021","unstructured":"Gaible C, Narjoz C, Loriot MA et al (2021) Pretherapeutic screening for Dihydropyrimidine deshydrogenase deficiency in measuring uracilemia in dialysis patients leads to a high rate of falsely positive results. Cancer Chemother Pharmacol 88:1049\u20131053. https:\/\/doi.org\/10.1007\/s00280-021-04354-7","journal-title":"Cancer Chemother Pharmacol"},{"key":"4518_CR22","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.jpba.2016.04.039","volume":"126","author":"BAW Jacobs","year":"2016","unstructured":"Jacobs BAW, Rosing H, de Vries N et al (2016) Development and validation of a rapid and sensitive UPLC-MS\/MS method for determination of uracil and dihydrouracil in human plasma. J Pharm Biomed Anal 126:75\u201382. https:\/\/doi.org\/10.1016\/j.jpba.2016.04.039","journal-title":"J Pharm Biomed Anal"},{"key":"4518_CR23","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1093\/chromsci\/bms085","volume":"50","author":"F Coudor\u00e9","year":"2012","unstructured":"Coudor\u00e9 F, Roche D, Lefeuvre S et al (2012) Validation of an ultra-high performance liquid chromatography tandem mass spectrometric method for quantifying uracil and 5,6-dihydrouracil in human plasma. J Chromatogr Sci 50:877\u2013884. https:\/\/doi.org\/10.1093\/chromsci\/bms085","journal-title":"J Chromatogr Sci"},{"key":"4518_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2022.115027","author":"SAH van den Wildenberg","year":"2022","unstructured":"van den Wildenberg SAH, Streng AS, van den Broek R et al (2022) Quantification of uracil, dihydrouracil, thymine and dihydrothymine for reliable dihydropyrimidine dehydrogenase (DPD) phenotyping critically depend on blood and plasma storage conditions. J Pharm Biomed Anal. https:\/\/doi.org\/10.1016\/j.jpba.2022.115027","journal-title":"J Pharm Biomed Anal"},{"key":"4518_CR25","doi-asserted-by":"publisher","first-page":"E112","DOI":"10.1515\/cclm-2021-0921","volume":"60","author":"S Capiau","year":"2022","unstructured":"Capiau S, van Landschoot A, Reyns T, Stepman H (2022) Pre-analytical considerations for the analysis of uracil and 5,6-dihydrouracil in heparin plasma. Clin Chem Lab Med 60:E112\u2013E115","journal-title":"Clin Chem Lab Med"},{"key":"4518_CR26","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1097\/FTD.0b013e318240405f","volume":"34","author":"IC C\u00e9sar","year":"2012","unstructured":"C\u00e9sar IC, Cunha-J\u00fanior GF, Duarte Byrro RM et al (2012) A rapid HPLC-ESI-MS\/MS method for determination of dihydrouracil\/uracil ratio in plasma: evaluation of toxicity to 5-flurouracil in patients with gastrointestinal cancer. Ther Drug Monit 34:59\u201366. https:\/\/doi.org\/10.1097\/FTD.0b013e318240405f","journal-title":"Ther Drug Monit"},{"key":"4518_CR27","doi-asserted-by":"publisher","DOI":"10.1080\/17843286.2020.1870855","author":"V Casneuf","year":"2021","unstructured":"Casneuf V, Borbath I, van den Eynde M et al (2021) Joint Belgian recommendation on screening for DPD-deficiency in patients treated with 5-FU, capecitabine (and tegafur). Acta Clinica Belgica: Int J Clin Lab Med. https:\/\/doi.org\/10.1080\/17843286.2020.1870855","journal-title":"Acta Clinica Belgica: Int J Clin Lab Med"},{"key":"4518_CR28","unstructured":"Haute Autorit\u00e9 de S (2018) Des recommandations pour pr\u00e9venir certaines toxicit\u00e9s s\u00e9v\u00e8res des chimioth\u00e9rapies par fluoropyrimidines"},{"key":"4518_CR29","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15536","author":"M Maillard","year":"2022","unstructured":"Maillard M, Launay M, Royer B et al (2022) Quantitative impact of pre-analytical process on plasma uracil when testing for dihydropyrimidine dehydrogenase deficiency. Br J Clin Pharmacol. https:\/\/doi.org\/10.1111\/bcp.15536","journal-title":"Br J Clin Pharmacol"},{"key":"4518_CR30","unstructured":"R Core Team (2020) (2020) R: A language and environment for statistical computing"},{"key":"4518_CR31","first-page":"3","volume":"31","author":"European Medicines Agency","year":"2020","unstructured":"European Medicines Agency (2020) EMA recommendations on DPD testing prior to treatment with fluorouracil, capecitabine, tegafur and flucytosine. EMA recommendations on DPD testing prior to treatment with fluorouracil, capecitabine, tegafur and flucytosine 31:3","journal-title":"EMA recommendations on DPD testing prior to treatment with fluorouracil, capecitabine, tegafur and flucytosine"},{"key":"4518_CR32","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.cca.2022.10.017","volume":"538","author":"L Tybirk","year":"2023","unstructured":"Tybirk L, Hoffmann-L\u00fccke E, Greibe E (2023) Instability of uracil in whole blood might affect cancer treatment with fluoropyrimidines. Clin Chim Acta 538:87\u201390. https:\/\/doi.org\/10.1016\/j.cca.2022.10.017","journal-title":"Clin Chim Acta"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-023-04518-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-023-04518-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-023-04518-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T07:04:56Z","timestamp":1679468696000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-023-04518-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["4518"],"URL":"https:\/\/doi.org\/10.1007\/s00280-023-04518-7","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"27 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest in the relationship with this work. Jos Beijnen is a (part-time) employee, stock- and patent holder of Modra Pharmaceuticals, a spin-out company developing oral taxane formulations; not related to the manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}